Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 45%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is a globally-recognized healthcare company, with a strong presence in the less invasive medical device market, where it holds a significant 91% market share in the US. We anticipate a slight growth slowdown in WATCHMAN sales, but we remain positive on the company's broad portfolio, healthy profitability metrics, and new product development, leading us to maintain a Buy rating with a 12-month price target of $57 at a P/E multiple of 16.0x 2027E adjusted EPS.

Bears say

Boston Scientific is facing significant challenges ahead, as management has signaled slowing sales for its key product, WATCHMAN, and has had to lower their revenue guidance due to market share losses and weak performance in the Interventional Oncology and Embolization segment. Additionally, the recent acquisition of MiRus and investment in Penumbra raise concerns about the company's allocation of capital and ability to achieve strong returns for shareholders. With sentiment towards the stock turning negative and multiple competitors in the same space, it may be difficult for Boston Scientific to regain its market position and drive significant growth in the coming years.

Boston Scientific (BSX) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 45% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 22 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Aug 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.